How far is the preoperative Kattan nomogram applicable for the prediction of recurrence after prostatectomy in patients presenting with PSA levels of more than 20 ng/ml? A validation study

Urologia Internationalis

Volumn 77, Issue 3, 2006, Pages 222-226

  May, M ^a,e   Gunia, S ^a   Helke, C ^a   Fuhrer S ^a   Hoschke, B ^a   Fahlenkamp, D ^b   Vogler, H ^c   Siegsmund, M ^d  

^a Carl Thiem Hospital   (Germany)

^b Department of Urology   (Germany)

^c VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^d VIVANTES KLINIKUM AM URBAN   (Germany)

^e Department of Urology   (Germany)

Author keywords

Kattan nomogram; Prostate cancer; Prostate specific antigen level, elevated; Prostatectomy; Risk of recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CALCULATION; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; EVALUATION; FOLLOW UP; GERMANY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; KATTAN NOMOGRAM; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; SURVIVAL RATE; SURVIVAL TIME;

AGED; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33750015201     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094813     Document Type: Article

References (9)

1. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771.
2. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN: Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168-172.
3. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-848.
4. Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schroder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW: International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002;20:3206-3212.
5. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-914.
6. Brandli DW, Koch MO, Foster RS, Bihrle R, Gardner TA: Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/ml) and clinically localized prostate cancer after radical prostatectomy. BJU Int 2003;92:19-22.
7. Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Erbersdobler A, Henke RP, Huland H, Wheeler TM, Slawin K, Scardino PT, Kattan MW: Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol 2004;171:200-203.
8. Miyake H, Hara S, Yamanaka N, Ono Y, Eto H, Yamada Y, Takechi Y, Arakawa S, Kamidono S, Hara I: Predicting the extent of prostate cancer using a combination of serum prostate-specific antigen-alpha(1)-antichy-motrypsin complex and systematic biopsy. Urol Int 2002;68:232-236.
9. Glaessgen A, Hamberg H, Pihl CG, Sundelin B, Nilsson B, Egevad L: Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens. Virchows Arch 2004;445:17-21.